People · Operator
Named in public records as an officer, director or promoter · active 2012–2024 · Biotech / Pharma, Pharmaceuticals, Medical Devices, Software / Tech, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vedanta Biosciences, Inc. | — | Biotech / Pharma | Series D+ | $240.3M | $2.0B | 2023 |
| Eyenovia, Inc. | — | Pharmaceuticals | Series C | $66.0M | $312.3M | 2016 |
| Cxl Ophthalmics, Inc. | — | Pharmaceuticals | Series B | $26.4M | $369.7M | 2022 |
| SafeOp Surgical, Inc. | — | Medical Devices | Series A | $10.9M | $136.4M | 2012 |
| InPress Technologies, Inc. | — | Software / Tech | Series A | $10.3M | $285.1M | 2018 |
| Novocuff, Inc. | — | Other Health Care | Series A | $6.8M | $33.4M | 2024 |
| Kurobe Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $5.0M | $154.9M | 2013 |
Curt LaBelle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Curt LaBelle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| BARRY BUTLER | 2 | 6 |
| Tsontcho Ianchulev | 2 | 5 |
| Shacey Petrovic | 2 | 3 |
| Ernest Mario | 1 | 9 |
| Anthony Sun | 1 | 8 |
| James L.L. Tullis | 1 | 6 |
| Michael Webb | 1 | 6 |
| Martin Heidecker | 1 | 6 |
| FRED ESHELMAN | 1 | 5 |
| NEIL TIWARI | 1 | 4 |
| Phyllis Whiteley | 1 | 3 |
| Troy Ignelzi | 1 | 3 |
| Bharatt Chowrira | 1 | 3 |
| Rachel Jacobson | 1 | 2 |
| Donald Lee | 1 | 2 |
| Marc Odrich | 1 | 2 |
| Richard O'Brien | 1 | 2 |
| Charles Mather | 1 | 2 |
| Fredric Eshelman | 1 | 2 |
| Kenneth Lee | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.